IP Verse

Methods For The Manufacture Of Proteolytically Processed Polypeptides - EP2677029

The patent EP2677029 was granted to Ipsen Bioinnovation on May 10, 2017. The application was originally filed on May 19, 2011 under application number EP13184864A. The patent is currently recorded with a legal status of "Revoked".

EP2677029

IPSEN BIOINNOVATION
Application Number
EP13184864A
Filing Date
May 19, 2011
Status
Revoked
Mar 29, 2024
Grant Date
May 10, 2017
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

ALLERGANFeb 9, 2018HOFFMANN EITLEADMISSIBLE

Patent Citations (8) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONWO0033863
DESCRIPTIONWO2009014854
OPPOSITIONEP2524963
OPPOSITIONUS5846929
OPPOSITIONWO2009014854
SEARCHUS2011086018
SEARCHWO0215700
SEARCHWO2009014854

Non-Patent Literature (NPL) Citations (45) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALTSCHUL, J MOL BIOL, (1990), vol. 215, page 403-
DESCRIPTION- DASGUPTA B. R. ET AL., TOXICON, (1984), vol. 22, no. 3, pages 414 - 424-
DESCRIPTION- DASGUPTA; SUGIYAMA, BIOCHEM. BIOPHYS. RES. COMMUN., (1972), vol. 48, pages 108 - 112-
DESCRIPTION- DASGUPTA, TOXICON, (1984), vol. 22, page 415-
DESCRIPTION- DEKLEVA; DASGUPTA; 1990, J. BACT., vol. 172, pages 2498 - 2503-
DESCRIPTION- DEKLEVA; DASGUPTA, BIOCHEM. BIOPHYS. RES. COMMUN., (1989), vol. 162, pages 767 - 772-
DESCRIPTION- EISELE ET AL., TOXICON, (2011), vol. 57, no. 4, pages 555 - 65-
DESCRIPTION- GALFRE; MILSTEIN, METH ENZYMOL, (1981), vol. 73, page 3-
DESCRIPTION- HABERMANN E; DREYER F; BIGALKE H., NAUNYN SCHMIEDEBERGS ARCH PHARMACOL., (1980), vol. 311, pages 33 - 40-
DESCRIPTION- HORI T ET AL., ACTA CRYSTALLOGR D BIOL CRYSTALLOGR, (2001), vol. 57, pages 361 - 368-
DESCRIPTION- JOST, DRUGS, (2007), vol. 67, no. 5, page 669-
DESCRIPTION- KOHLER; MILSTEIN, NATURE, (1975), vol. 256, page 495-
DESCRIPTION- KOZAKI ET AL., INFECT. IMMUN., (1974), vol. 10, pages 750 - 756-
DESCRIPTION- KRIEGLSTEIN, EUR J BIOCHEM, (1990), vol. 188, page 39-
DESCRIPTION- KRIEGLSTEIN, EUR J BIOCHEM, (1991), vol. 202, page 41-
DESCRIPTION- KRIEGLSTEIN, J PROTEIN CHEM, (1994), vol. 13, page 49-
DESCRIPTION- K. SUGIMURA; T. NISHIHARA., J. BACTERIOL., (1988), vol. 170, pages 5625 - 5632-
DESCRIPTION- LACY ET AL., NAT. STRUCT. BIOL., (1998), vol. 5, no. 10, pages 898 - 902-
DESCRIPTION- MALMBORG ET AL., J. IMMUNOL METHODS, (1995), vol. 183, page 7-
DESCRIPTION- MITCHEL; HARRINGTON, JBC, (1968), vol. 243, pages 4683 - 4692-
DESCRIPTION- NILSSON ET AL., ANN. REV. BIOPHYS. BIOMOL. STRUCT., (2005), vol. 34, pages 91 - 118-
DESCRIPTION- NONAKA T ET AL., J BIOCHEM., (1998), vol. 124, pages 157 - 162-
DESCRIPTION- NONAKA T ET AL., J BIOL CHEM., (1997), vol. 272, pages 30032 - 30039-
DESCRIPTION- PEARCE LB; BORODIC GE; FIRST ER; MACCALLUM RD, TOXICOL APPL PHARMACOL, (1994), vol. 128, pages 69 - 77-
DESCRIPTION- Remington's Pharmaceutical Sciences, MACK PUBLISHING COMPANY-
DESCRIPTION- RUMMEL ET AL., MOL MICROBIOL., (2004), vol. 51, pages 631 - 43-
DESCRIPTION- SATHYAMOORTHY, J BIOL CHEMISTRY, (1985), vol. 260, page 10461-
DESCRIPTION- SCHIER ET AL., HUMAN ANTIBODIES HYBRIDOMAS, (1996), vol. 7, page 97-
DESCRIPTION- SEBAIHIA ET AL., GENOME RES., (2007), vol. 17, no. 7, pages 1082 - 1092-
DESCRIPTION- SHONE ET AL., EUR. J. BIOCH., (1985), vol. 151, pages 75 - 82-
DESCRIPTION- WRIGHT DS; GRAHAM LD; JENNINGS PA, BIOCHIM BIOPHYS ACTA, (19981222), vol. 1443, no. 3, pages 369 - 74-
OPPOSITION- "Endoproteinase Lys-C Product information", Roche, (20110300), XP055463912-
OPPOSITION- ICHTCHENKO et al., "Full-length clostridium botulinum neurotoxin serotype a derivatives with native structure and properties", Neurotox Res, (20060400), vol. 9, no. 2-3, page 234, XP055463838-
OPPOSITION- KIM et al., "Characterization of a unique IgG1 mAb CEX profile by limited Lys-C proteolysis/CEX separation coupled with mass spectrometry and structural analysis", J Chrom B, (20100000), vol. 878, pages 1973 - 1981, XP027118640-
OPPOSITION- SIGMA ALDRICH, "Endoproteinase Lys-C from Lysobacter enzymogenes suitable for Protein Sequencing product Information", Sigma-Aldrich, (20140000), XP055463854-
OPPOSITION- LACY et al., "Sequence homology and structural analysis of the clostridial neurotoxins", J Mol Biol, (19990000), vol. 291, pages 1091 - 1104, XP004461909
OPPOSITION- KRIEGLSTEIN et al., "COVALENT STRUCTURE OF BOTULINUM NEUROTOXIN TYPE A: LOCATION OF SULFHYDRYL GROUPS, AND DISULFIDE BRIDGES AND IDENTIFICATION OF C-TERMINI OF LIGHT AND HEAVY CHAINS", J Protein Chemistry, (19940000), vol. 13, no. 1, pages 49 - 57, XP000942365
OPPOSITION- GIMENEZ et al., "Botulinum neurotoxin type E fragmented with endoproteinase Lys-C reveals the site trypsin nicks and homology with tetanus neurotoxin", Biochimie, (19900000), vol. 72, pages 213 - 217, XP025458768
OPPOSITION- GADGIL et al., "Identification of cysteinylation of a free cysteine in the Fab region of a recombinant monoclonal IgG1 antibody using Lys-C limited proteolysis coupled with LC/MS analysis", Analytical Biochemistry, (20060000), vol. 355, pages 165 - 174, XP024942076
OPPOSITION- SATORIUS et al., "Activation time-course and in vivo pharmacological analysis of native BoNT/E", Toxicon, (20080000), vol. 51, page 20, XP022695747
OPPOSITION- JENSEN et al., "Expression, purification, and efficacy of the type A botulinum neurotoxin catalytic domain fused to two translocation domain variants.", Toxicon, (20030000), vol. 41, pages 691 - 701, XP001156776
OPPOSITION- KOZAKI et al., "Activation of Clostridium botulinum type B and E derivative toxins with lysine-specific proteases", FEMS Microbiology Letters, (19850000), vol. 27, pages 149 - 154, XP023919407
SEARCH- KIM J ET AL, "Characterization of a unique IgG1 mAb CEX profile by limited Lys-C proteolysis/CEX separation coupled with mass spectrometry and structural analysis", JOURNAL OF CHROMATOGRAPHY B: BIOMEDICAL SCIENCES & APPLICATIONS, ELSEVIER, AMSTERDAM, NL, vol. 878, no. 22, ISSN 1570-0232, (20100715), pages 1973 - 1981, (20100601), XP027118640 [A] 1-16 * abstract * * page 1974 *-
SEARCH- GIMENEZ J A ET AL, "Botulinum neurotoxin type E fragmented with endoproteinase Lys-C reveals the site trypsin nicks and homology with tetanus neurotoxin", BIOCHIMIE, MASSON, PARIS, FR, vol. 72, no. 4, doi:10.1016/0300-9084(90)90075-R, ISSN 0300-9084, (19900401), pages 213 - 217, (19900401), XP025458768 [X] 1-16 * the whole document *
SEARCH- KOZAKI S ET AL, "Activation of Clostridium botulinum type B and E derivative toxins with lysine-specific proteases", FEMS MICROBIOLOGY LETTERS, WILEY-BLACKWELL PUBLISHING LTD, GB, vol. 27, no. 2, doi:10.1111/J.1574-6968.1985.TB00658.X, ISSN 0378-1097, (19850501), pages 149 - 154, (19850501), XP023919407 [X] 1-16 * abstract * * page 149, column 2, paragraph 2 * * page 151 - page 153 *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents